As for common pathways, we found that there were 105 overlaps between agents from GWAS and transcriptome data, of which 60.9% were immunomodulatory drugs, including IL inhibitors, JAK-STAT inhibitors, recombinant IL, and INF, suggesting their potential therapeutic effects on MS and SS, especially on their comorbidity. The gene discussed is SOAT1; the disease is myeloid sarcoma.